Skip to content

In the BioHarmony Drug Report Database

Ravulizumab

Ultomiris (ravulizumab) is an antibody pharmaceutical. Ravulizumab was first approved as Ultomiris on 2018-12-21. It is used to treat atypical hemolytic uremic syndrome in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. It is known to target complement C5.
Trade Name Ultomiris
Common Name Ravulizumab
Indication atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria
Drug Class Monoclonal antibodies: humanized, immunomodulating
Ravulizumab
Get full access now